Thursday, December 15, 2011

Multiple Myeloma Life Expectancy, Multiple Myeloma Prognosis


All the forms of cancer are characterized by individual malignant development of a specific type of cell in the body. There are both red and white blood cells present in the human body. The main function of white blood cells is to battle against infection by generating antibodies. The plasma cell is a type of white blood cell and it is found in the soft centers of bones. Usually, plasma cell tumors affect the hip bones, ribs, spine, and skull. Moreover, the body abnormally develops huge rates of positive antibodies to fight against worst situations. As one of the plasma cells convert to cancerous cells and multiply themselves, the multiple myeloma cancer forms. The irregular expansion of plasma cells has an effect on the generation of platelets and also on the red and white blood cells. This leaves the patients in an anemic condition. Multiple myeloma is also known as Kahler’s disease.

Various stages determining Multiple Myeloma life expectancy
The multiple myeloma life expectancy is mainly dependent on the different stages of the disease. With the progression of cancer the survival period starts lessening. Based on the standards of serum albumin and serum beta-2 micro globulin in the blood, multiple myeloma can be divided into various multiple myeloma stages. The level of these two proteins is a sign of the amount of propagation achieved by the cancer cells.



The stage wise survival percentage that is specified here is based on figures and is a median value. Exact forecast of multiple myeloma life expectancy cannot be defined easily as it depends on several issues which are mentioned in the Multiple Myeloma Prognosis. A person’s multiple myeloma life expectancy will vary roughly around the median values predicted below according the different stages of development of the disease.

Stage 1: patients effected with multiple myeloma having albumin levels upper than 3.5, but beta-2 globulin levels less than 3.5 and fall under the first stage of multiple myeloma growth. The median multiple myeloma life expectancy for these patients is the uppermost, which is 62 months after discovery or detection of the disease.
Stage 2: the patients with beta-2 globulin levels in between 3.5 and 5.5 fall under the second stage of multiple myeloma expansion. The median multiple myeloma life expectancy for these patients is 44 months after detection.
Stage 3: Patients with beta-2 micro globulin levels greater than 5.5 can be graded in the third stage of multiple myeloma development. The median multiple myeloma life expectancy for these patients is the lowest, which is 29 months after detection.

It is, however, said that, at an average, the Prognosis For Multiple Myeloma ranges from five years to eight years, after the diagnosis starts. This, is just n average rate, and it is often much higher or much lower and that depends on the stage at which the disease is detected and treatment is started. In 2002, a survey was carried out in the United Kingdom by the European Cancer Register and the survey stated that only 30 out of 100 patients who are affected with multiple myeloma cancer, survived for a period over 5 years.

No comments:

Post a Comment